One hundred and sixteen BC including 55 HER2 clearly amplified (>6.0 gene s/n) and 61 clearly non amplified (less than 4.0 gene s/n, ratio < 2.0) BC represented our control series. This evidence concerns the gene ERBB2 and breast cancer.